Mounting evidence supports CB1R antagonism as a key pharmacological mechanism to block the overactivation of the eCB signaling system for the treatment of obesity and its cardiometabolic complications, such as NAFLD and T2D. The gene discussed is CNR1; the disease is metabolic dysfunction-associated steatotic liver disease.